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Background: Peritoneal fibrosis is a common complication in patients treated with long-term peritoneal dialysis.
The aim of this study was to identify the microRNAs (miRNAs) involved in regulation of peritoneal fibrosis in a rat
model of peritoneal dialysis.
Methods: Twenty-four Sprague–Dawley (SD) rats were randomly allocated into three groups: (i) Control group
(Cg, n = 8); (ii) Saline group (Sg, n = 8): daily intraperitoneal injection with 0.9% normal saline; (iii) Hypertonic dialysate
group (HDg, n = 8): daily intraperitoneal injection with 4.25% peritoneal dialysis solution. Rats were sacrificed after four
weeks for histological evaluation of peritoneal membrane and the expression of α-SMA and COL-1. A miRNA screen
was performed using microarray analysis to identify differentially expressed miRNAs, which were then validated by
real-time PCR.
Results: Compared with the control and the saline groups, hypertonic dialysate group showed impaired peritoneal
function accompanied by a spectrum of morphological changes including thicker peritoneal membrane, higher collagen
deposition, infiltration of mononuclear cells and neovascularization in the peritoneum. Increased mRNA and protein
levels of α-SMA and COL-1 were observed in hypertonic dialysate group, indicating the progression of peritoneal fibrosis.
The miRNA screen identified 8 significantly down-regulated miRNAs (miR-31, miR-93, miR-100, miR-152, miR-497,
miR-192, miR-194 and miR-200b) and one highly up-regulated miRNA (miR-122) in the hypertonic dialysate group.
The results were confirmed by real-time PCR.
Conclusions: Altered miRNA expression in peritoneum was found in the rat model of peritoneal fibrosis, indicating that
these miRNAs may be associated with pathogenesis of peritoneal fibrosis.
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Peritoneal dialysis (PD) has been adopted worldwide as a
renal replacement treatment for patients with chronic
kidney disease. It has been used as an alternative to
hemodialysis due to its advantages in controlling blood
pressure and maintaining electrolyte balance [1,2]. In
addition, PD does not require routine visits to a hospital
or medical facility and thus offers a better quality of life
and lower cost to the patients [3,4]. However, long-term
PD is usually associated with development of structural
and functional alterations in the peritoneal membrane* Correspondence: drchaoxinghuang@gmail.com
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article, unless otherwise stated.[5,6]. Several risk factors for development of peritoneal
fibrosis in PD patients have been implicated, including
the bioincompatibility of hyperglycemic PD solutions,
recurrent peritonitis, and increased concentration of growth
factors such as FGF-2, TGF-β, CTGF, VEGF, etc. [7,8].
These factors may result in changes in the morphology of
the peritoneal mesothelial cells and sediment of the
extracellular matrix in peritoneum, and those changes
ultimately lead to peritoneal fibrosis and ultrafiltration
failure. Therefore, prevention and treatment of peritoneal
fibrosis are critical to maintain the peritoneal membrane
integrity and prolong PD treatment in patients. Recent
studies have demonstrated that the anti-fibrogenic
strategies, such as development of a more biocompatibledistributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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and inhibition of the renin-angiotensin system, have the
potential to attenuate or prevent the onset of peritoneal
fibrosis in multiple animal models [9-12].
miRNAs are 19 to 25-nucleotide, non-coding RNA
transcripts, and thought to be instrumental in controlling
eukaryotic cell functions by modulating the post-
transcriptional activity of target mRNAs through
translational repression or mRNA degradation [13,14].
Because of the sophisticated roles miRNAs play in
regulating various basic cellular processes such as
proliferation, differentiation and apoptosis, dysregulation
of miRNAs has been associated with a wide spectrum of
human malignancies [15,16]. Recently, the involvement of
miRNAs in different fibrotic disorders, including systemic
sclerosis, liver cirrhosis, cardiac fibrosis and idiopathic
pulmonary fibrosis, has attracted a considerable amount
of attention [17-22]. There is accumulating evidence that
shows the miRNA-regulated epithelial-to-mesenchymal
transition (EMT) in human peritoneal mesothelial cells,
which has been indicated by previous research as a key
mechanism for the development and progression of
peritoneal fibrosis [23-25]. Furthermore, recent studies
have discovered the enrichment of specific extracellular
miRNAs in peritoneal dialysis effluent, implying the
potential of those miRNAs as diagnostic biomarkers
[26-28]. More direct evidence comes from a study
using a mouse model of peritoneal dialysis, in which
microRNA-29 (miR-29) was identified to be an
inhibitor of peritoneal fibrosis through suppression of
TGF-β signaling pathway [29]. Therefore, it will be
great interest to perform a comprehensive miRNA
screen to identify additional regulatory candidates
and examine their roles in pathogenesis of peritoneal
fibrosis.
In this study, we performed an extensive screen to
identify miRNAs with potential regulatory function in
peritoneal fibrosis using a rat PD model. This study set
the foundation for further exploration of the miRNA
machinery in peritoneal fibrosis and for development of
targeted therapy in PD patients.
Methods
Animals
Male SD rats weighing 140 to 160 g were purchased
from SLAC Laboratory Animals Co (Shanghai, China).
They were allowed to acclimatize for 1 week before the
beginning of the experiment. Animals were maintained
under specific pathogen free (SPF) conditions and allowed
free access to food and water. All animal experiments in
this study were approved by the Animal Care Committee of
the Wenzhou Medical College of China (SCXK2007-0005)
and conducted in accordance with “Recommendations
on the Establishment of Animal Experimental Guidelines”approved at the 80th General Assembly of the Japanese
Science Council in 1980.
Twenty-four SD rats were randomly divided into three
groups: (i) Control group (Cg, n = 8); (ii) Saline group
(Sg, n = 8): daily intraperitoneal injection with 0.9%
normal saline; (iii) Hypertonic dialysate group (HDg, n = 8):
daily intraperitoneal injection with 4.25% peritoneal dialysis
solution (Baxter HealthCare, Deerfield, IL, USA). The
volume of saline and 4.25% peritoneal dialysis solutions
used in daily injection was 20 ml. The duration of treat-
ment was four weeks for establishment of peritoneal fibro-
sis, which was determined by earlier studies and our
previous observation [30,31].Peritoneal function test and sample collection
After four weeks of treatment, a 2-hour peritoneal
equilibration test (PET) was performed. During each
PET, rats were given 20 ml of 4.25% glucose peritoneal
dialysis solution (PDS) via a 20-gauge needle into the
peritoneal cavity. Dialysate samples (1 ml) were taken at
2 hours after infusion. Blood samples were taken from
the inferior vena cava at the end of the PET. During the
PET, animals were awake and had free access to water
and food.
The dialysate and blood samples were centrifuged and
stored at −20°C until assayed. Concentrations of creatinine
and glucose in serum and dialysate were measured by
enzymatic methods using a Hitachi 7600–110 Automated
Biochemistry analyzer (Hitachi, Tokyo, Japan). Net ultrafil-
tration (UF) was determined as the volume of fluid
removed after the 2-hour PET subtracted by the volume
of fluid administered. The efficiency of solute transport
across the peritoneal membrane was determined by
glucose reabsorption (D2/D0, concentration of glucose in
dialysate at 2 hours relative to that in the infused dialysis
solution) and creatinine transport (D/Purea, dialysate to
plasma concentration ratio of creatinine at 2 hours).
Following sample collection, all rats were sacrificed by
bleeding from the abdomen. The peritoneal cavity was
opened with minimal handling or trauma, and tissues of
the visceral and parietal peritoneum were taken for further
measurement.Cytologic examination and histology
White blood cell count in peritoneal effluent was obtained
using an Olympus CX31 microscope (Olympus, Tokyo,
Japan).
Each peritoneum was fixed with 4% paraformaldehyde
solution and processed for paraffin embedding. Tissue
sections (4 μm) were then stained with hematoxylin and
eosin and Masson’s trichrome stain for histological
examination of peritoneal mesothelial cells, thickness of
the peritoneal tissues, inflammatory cell infiltration, and
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Immunohistochemical staining of the peritoneum
For immunohistochemistry (IHC), tissue sections were
deparaffinized, rehydrated, and incubated with 3%
hydrogen peroxide to inhibit the activity of endogenous
peroxidase. The sections were then incubated with primary
antibodies against α-SMA and COL-1 (Abcam, Cambridge,
MA, USA) overnight at 4°C. On the next day, the sections
were incubated with biotin-conjugated secondary
antibodies, followed by incubation with horseradish
peroxidase (HRP)-conjugated streptavidin. The resultant
primary-secondary antibodies-biotin-streptavidin-HPR com-
plex was then stained with diaminobenzidine (DAB),
which led to reddish-brown stains representing positive
immunoreactions. The reaction was interrupted by rinsing
with distilled water. Samples were then contrasted with
Mayer hematoxylin and examined using an optic
photomicroscope at a magnification of 400X. To include a
negative control, phosphate buffered saline (PBS) was
used in place of the primary antibodies. For each tissue
section, 10 different images were randomly selected and
analyzed by semi-quantitative assessment using the
Image-Pro Plus 6.0 software (Media Cybernetics, Inc.,
Rockville, MD, USA). The mean optical density was
calculated by the overall optical density from all positive
staining divided by total area.
RNA extraction and quality determination
Total RNA was extracted from the peritoneum of rats
using the Trizol Reagent according to the manufacturer’s
instructions (Invitrogen, Grand Island, NY, USA). The
RNA concentration and purity were determined using a
Varioskan Flash Multimode Reader (Thermo Scientific,
Waltham, MA, USA). The concentration of total RNA
(μg/ml) was calculated using the formula: OD260 X
dilution factor X 40 μg/ml. An OD260/280 ratio between
1.9 and 2.1 was considered an indication of high quality
RNA, thereby making the RNA sample suitable for gene
expression analysis. RNA integrity was also assessed using
the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa
Clara, CA, USA), which detected the integrity of 18S and
28S RNA peaks.
Microarray analysis
For each sample, 500 ng of total RNA was labeled
using the FlashTag Biotin HSR RNA Labeling Kit and
prepared for the GeneChip miRNA Arrays according
to the manufacturer’s recommendations (Genisphere,
Hartfield, PA, USA).
After labeling, samples were hybridized on the Affymetrix
GeneChip miRNA 2.0 Arrays (Affymetrix, Santa Clara,
CA, USA) in a volume of 100 μl reaction mix at 48°C and60 rpm for 16 hours. Immediately following hybridization,
the arrays were washed and stained with streptavidin-
phycoerythrin conjugates in the GeneChip Fluidics Station
450. Finally, the arrays were scanned using a GeneChip
Scanner 3000 7G (Affymetrix).
The microarray data were analyzed using the Affymetrix
GeneChip Command Console (AGCC) software. Fold
changes higher than 2 or lower than 0.5 were considered
to be significantly different between two groups.
Real-time PCR analysis
RNA expression in visceral peritoneum was evaluated by
real-time PCR analysis. cDNA was synthesized from the
purified total RNA using a cDNA Reverse Transcription
Kit (Thermo Scientific) according to the manufacturer’s
instructions. cDNA was amplified using the SYBR
Green PCR Master mix in a 7500 Real-Time System
(Applied Biosystems, Grand Island, NY, USA). Relative
expressions of mRNA and miRNA were calculated using
the 7500 Real-Time System software.
For miRNA, the real-time PCR reaction was maintained
at 95°C for 3 min, followed by 95°C for 5 s and 60°C for
35 s for 40 cycles. For mRNA, the real-time PCR reaction
was maintained at 95°C for 3 min, followed by 95°C for 15
s and 60°C for 1 min for 40 cycles. The dissociation curves
were analyzed to ensure amplification of a single PCR
product. In order to ensure reliability of the results, all
samples were processed in triplicate. Quantification
was performed by the comparative cycle threshold
(Ct) method [32]. To normalize the data, the GAPDH
mRNA and the U6 miRNA were used as housekeeping
genes. The sequences of PCR primers are listed in
Additional files 1 and 2.
Statistical analysis
Statistical analysis was performed using the SPSS 18
software (IBM, Armonk, New York, USA). All numerical
results were expressed as the mean ± standard deviation
(SD). Comparison between groups was made by one-way
analysis of variance (ANOVA). Pairwise comparison was
made by Tamhane’s T2 test. A value of P <0.05 was
considered statistically significant.
Results
Hypertonic dialysate group had reduced ultrafiltration
capacity
Net ultrafiltration (UF) was measured in a 2-hour PET
after four weeks of dialysis treatment. Compared with
the control group and the normal saline group, the
hypertonic dialysate group showed significantly reduced UF
capacity and glucose reabsorption (D2/D0) while increased
dialysate-to-plasma urea ratio (D/Purea) (all P <0.05)
(Table 1). These results indicated that the peritoneal
Table 1 Peritoneal function test in three groups after four
weeks treatment
Groups N UF (ml) D2/D0 D/Purea
Control 8 27.97 ± 1.11 0.28 ± 0.04 0.12 ± 0.03
Saline 8 28.40 ± 0.95 0.27 ± 0.03 0.12 ± 0.05
Hypertonic dialysate 8 10.53 ± 0.75*# 0.14 ± 0.02*# 0.42 ± 0.05*#
*compared with the control group, P <0.05.
#compared with the saline group, P <0.05.
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toneal dialysis.
Hypertonic dialysate group showed morphological
changes of peritoneum
White blood cell count in peritoneal effluent was
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Figure 1 Histological examination of rat peritoneum and expression of α-S
staining (original magnification: X200) of peritoneum isolated from the c
dialysate group (C1). (A2, B2 and C2) Masson’s trichrome staining (origi
group (A2), the normal saline group (B2), and the hypertonic dialysate group
the hypertonic dialysate group had increased collagen deposition compa
(original magnification: X400) of peritoneum from the control group (A3),
(C3). (A4, B4 and C4) COL-1 staining (original magnification: X400) of per
(B4), and the hypertonic dialysate group (C4).all three groups, the white blood cell count was lower than
100/mm3 when examined using an optic microscope, indi-
cating that no rats in three groups developed peritonitis.
To assess the potential structural change induced
by hypertonic dialysis in the peritoneal membrane,
histological examination was performed in tissue sam-
ples of peritoneum obtained from the three groups.
The peritoneal membrane in the control and saline
groups appeared as a monolayer of mesothelial cells
(Figure 1,A1 and B1). However, the peritoneum was
thicker and appeared more edematous in the hypertonic
dialysate group (Figure 1,C1). Mononuclear cell infiltration,
fibroblastic activation, neovascularization and interstitial
edema were more prominent in the hypertonic dialysate
group than in the control and saline groups. The re-
sults from Masson’s trichrome staining showed thatSaline                             Hypertonic dialysate
MA and COL-1 after four weeks treatment. (A1, B1 and C1) H&E
ontrol group (A1), the normal saline group (B1), and the hypertonic
nal magnification: X200) of parietal peritoneum isolated from the control
(C2). Collagen was stained green. Note that the peritoneum from
red with the other two groups. (A3, B3 and C3) α-SMA staining
the normal saline group (B3), and the hypertonic dialysate group
itoneum from the control group (A4), the normal saline group
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the peritoneal membrane was much thicker in the
hypertonic dialysate group than in the control and saline
groups (Figure 1,A2,B2 and C2).
Hypertonic dialysate group had increased expression of
EMT markers
During peritoneal fibrosis, mesothelial cells acquire a
fibroblast-like phenotype in a process called EMT, which
is critical in driving changes in extracellular matrix.
Alpha-smooth muscle actin (α-SMA) and type I collagen
(COL-1) are mesenchymal markers, the expression of
which corresponds to morphological changes in the
peritoneum [33,34]. α-SMA (Figure 1,A3,B3 and C3) and
COL-1 (Figure 1,A4,B4 and C4) were highly expressed
in the peritoneal mesothelial cells, peritoneal mesothe-
lium matrix, infiltrated inflammatory cells, and vascular
endothelial cells in the hypertonic dialysate group.
When using the semi-quantitative imaging software to
analyze the staining intensity, the hypertonic dialysate
group showed significantly higher expression of α-SMA
and COL-1 compared with the control and saline groups
(all P <0.05) (Table 2). No significant differences in expres-
sion of α-SMA and COL-1 between the control and saline
groups were observed (all P >0.05). The results from IHC
were further validated in mRNA level by real-time PCR.
Consistently, α-SMA and COL-1 levels showed no signifi-
cant differences between the control and saline groups
(all P >0.05) (Figure 2). In contrast, expression of α-
SMA and COL-1 were both up-regulated in the
hypertonic dialysate group (all P <0.05) (Figure 2).
Additional EMT marker vimentin [35] was also investi-
gated, and highly up-regulated expression was observed
in the hypertonic dialysate group (Figure 2). These results
demonstrated that the progression of peritoneal fibrosis
was accompanied by morphological changes and develop-
ment of EMT in rat peritoneum treated with hypertonic
dialysate.
Microarray analysis identified differentially expressed
miRNAs
An extensive miRNA screen was performed to identify
miRNAs which were differentially regulated during the
process of peritoneal fibrosis. The results were analyzedTable 2 Expression of α-SMA and COL-1 (measured by
mean optical density) after four weeks treatment
Groups α-SMA COL-1
Control 0.0222 ± 0.0114 0.0433 ± 0.0058
Saline 0.0454 ± 0.0090† 0.0509 ± 0.0015†
Hypertonic dialysate 0.1464 ± 0.0052*# 0.1379 ± 0.0037*#
*Compared with the control group, P <0.05.
#Compared with the saline group, P <0.05.
†Compared with the control group, P >0.05.by making comparisons between the hypertonic dialysate
and saline groups, between the hypertonic dialysate and
control groups, and between the saline and control
groups. It was found that 8 miRNAs were significantly and
consistently down-regulated in the hypertonic dialysate
group (miR-31, miR-93, miR-100, miR-152, miR-497,
miR-192, miR-194 and miR-200b), and within which
miR-192, miR-194 and miR-200b were also down-regulated
in the normal saline group (Table 3). Significantly increased
expression of miR-122 was observed in the hypertonic
dialysate group compared with the saline and control
groups (Table 3).
Real-time PCR analysis validated the results from
microarray
Relative expression of the miRNAs identified from
microarray analysis was measured by real-time PCR. The
results demonstrated that in the hypertonic dialysate
group, miR-31, miR-93, miR-100, miR-152, miR-497,
miR-192, miR-194 and miR-200b were all significantly
down-regulated whereas miR-122 was highly up-regulated
(all P <0.05) (Figure 3). These results were consistent with
those from microarray analysis. However, no significant dif-
ferences in miRNA expression were observed between the
control and normal saline groups (all P >0.05) (Figure 3).
Discussion
In the present study, a rat model of peritoneal fibrosis
was successfully established through daily intraperitoneal
injection of 4.25% hypertonic dialysate for 4 weeks. This
model has been widely used in numerous previous studies
and provides valuable information needed to understand
the pathological process of peritoneal fibrosis induced by
peritoneal dialysis fluid [30,31]. Compared to the peritoneal
dialysis performed through abdominal cavity intubation
with a catheter, intraperitoneal injection of dialysate has
many advantages such as lower cost, higher feasibility and
reduced risk of developing exit site infection. In order to
assess the potential impact of peritoneal mechanical injury
caused by daily injection, a saline group in which the rats
received daily peritoneal injection of saline solutions was
used and compared to the untreated control group.
Our results showed that there were no significant
differences in all the indicators of peritoneal fibrosis
between saline and untreated control groups, suggest-
ing that the peritoneal mechanical injury was not a
confounding factor in our study.
Progression of dialysis-induced peritoneal fibrosis in
our rat model led to impaired peritoneal function,
which was indicated by reduced ultrafiltration capacity, de-
creased glucose reabsorption (D2/D0) and higher dialysate-
to-plasma urea ratio (D/Purea). During the histological
examination, we observed thicker peritoneal membrane
and higher collagen deposition. Pathogenesis of peritoneal
Figure 2 Relative expression of α-SMA, COL-1 and vimentin in visceral peritoneum after four weeks treatment. Relative mRNA expression (%)
of α-SMA, COL-1 and vimentin was measured by real-time PCR analysis and comparisons were made between the control, normal saline and
hypertonic dialysate groups. The results are presented as mean ± SD from 3 independent experiments. The differences in expression of α-SMA,
COL-1 and vimentin between the saline group and the hypertonic dialysate group were significant (all P <0.05).
Lin et al. BMC Nephrology  (2015) 16:48 Page 6 of 9fibrosis is accompanied by a series of cellular changes
including mononuclear cell infiltration, fibroblastic
activation, neovascularization and interstitial edema,
and all these changes were more prominent in the
hypertonic dialysate group. The expression levels of
α-SMA, COL-1 and vimentin were all markedly higher in
the hypertonic dialysate group, indicating that the peritoneal
mesothelial cells had acquired a mesenchymal phenotype
through the process of EMT and had enhanced production
of extracellular matrix components [36]. In an effort to
identify potential regulators of peritoneal fibrosis, a miRNA
screen was performed, which represented a parallel and
high-throughput method of detecting hundreds of miRNAs
simultaneously. Quantitative real-time PCR is the golden
standard for gene expression quantification and thus used
in our study to validate the results from microarray
analysis [37]. Compared with the control and saline
groups, both miRNA microarray and real-time PCR
analyses demonstrated that miR-31, miR-93, miR-100,Table 3 Change of microRNA expression by microarray
analysis in three groups after four weeks treatment
HDg vs. Sg HDg vs. Cg Sg vs. Cg
Down-regulated Fold-change Fold-change Fold-change
rno-miR-31 0.37* 0.42* /
rno-miR-100 0.45* 0.40* /
rno-miR-93 0.45* 0.48* /
rno-miR-152 0.38* 0.40* /
rno-miR-497 0.33* 0.44* /
rno-miR-192 / 0.24* 0.28*
rno-miR-194 / 0.14* 0.12*
rno-miR-200b / 0.19* 0.27*
Up-regulated Fold-change Fold-change Fold-change
rno-miR-122 3.87* 2.49* /
*indicates significant difference between the two groups.
/indicates no significant difference between the two groups.miR-152, miR-497, miR-192, miR-194 and miR-200b
were significantly down-regulated, and miR-122 was
highly up-regulated in the hypertonic dialysate group.
Overall, the results from microarray analysis correlated
well with those from real-time PCR, which demonstrates
the reliability of the miRNA screen and warrants further
investigation.
The role of miRNAs in tissue fibrosis has been previously
studied in multiple animal models and patients with
fibrotic diseases. In a mouse model of pulmonary fibrosis,
miR-31 was shown to be down-regulated in the fibroblasts
[38]. This result is consistent with ours in the rat model of
peritoneal fibrosis. Furthermore, miR-31 was identified as a
direct modulator of integrin-α(5) and RhoA, two critical
activators of the migratory activity of fibroblasts [38].
These results provide us a clue to find out the targets of
miR-31 in peritoneum. In patients with renal fibrosis and
IgA nephropathy, the urinary miR-93 level correlated with
the degree of glomerular scarring and was regulated by the
TGF-β1/SMAD3 pathway [39]. However, miR-93 was
found to be up-regulated in patients with renal fibrosis,
which is the opposite of our finding in peritoneal fibrosis.
The function of miR-93 in tissue fibrosis might be context-
dependent and tissue specific. The exact mechanism by
which miR-93 regulates the development of progressive
renal and peritoneal fibrosis needs further investigation.
Decreased expression of miR-192 was detected in patients
with established diabetic nephropathy, and its expression
level correlated with the degree of tubulointerstitial fibrosis
[40]. However, opposite results were shown in a kidney
disease model of obstructive nephropathy, in which over-
expression of Smad7 inhibited the expression of miR-192
and resulted in suppression of renal fibrosis [41]. Further
studies are needed to elucidate how miR-192 exhibits its
inhibitory activity on peritoneal fibrosis. miR-194 has been
associated with liver fibrosis in a rat model. It was found to
be down-regulated in fibrotic liver, similar as we observed
in peritoneal fibrosis [42]. Introduction of miR-194 in
Figure 3 Relative expression of miRNA candidates in three groups after four weeks treatment. Relative expression of miRNAs (%) was measured
by real-time PCR analysis and comparisons were made between the control, normal saline and hypertonic dialysate groups. The results are
presented as mean ± standard deviation from 3 independent experiments.
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expression of α-SMA and COL-1 [42]. These results
are consistent with our findings and future studies
should focus on elucidating how the targets of miR-194
might be involved with modulation of α-SMA and COL-1
activation. The roles of miR-200 family in EMT and fibro-
genesis have been well defined by previous research
[43,44]. miR-200a was shown to inhibit EMT and renal
fibrosis in a TGF-β-induced diabetic kidney model
[45]. Administration of miR-200b could suppress the
fibrogenesis of intestinal epithelial cells in vitro and
ameliorate renal fibrosis in a mouse model of tubulointer-
stitial fibrosis [46,47]. Taken together, these results suggest
to us that the miRNA species identified in our miRNA
screen (mir-31, mir-93, mir-192, mir-194 and mir-200b)
may be critical in the process of mesothelial cell EMT and
in the progression of peritoneal fibrosis. Identification of
their molecular targets and exploration of the mechanism
by which those downstream molecules coordinate to
modulate fibrogenesis deserve further study.
miR-122 is the only miRNA identified to be significantly
up-regulated in our rat model of hypertonic dialysate-
induced peritoneal fibrosis. As the most abundant miRNA
species in hepatocytes, the role of miR-122 in fibrogenesis
has been well studied in liver models. The results suggest
that miR-122 may contribute to the regulation of tissue
remodeling, collagen production and pathogenesis of
diet- or hepatitis C virus-induced liver fibrosis [48-50].
Studies of miR-122 in other tissues or disease models are
extremely limited. Our result provides additional evidence
supporting the role of miR-122 in fibrogenesis.
A recent study identified miR-29b, a downstream
inhibitor of TGF-β signaling, as a negative regulator
of mouse peritoneal fibrosis [29]. Presence of miR-29b has
also been detected specifically in human peritoneal fluid
[27]. miR-29b is a member of the miR-29 family which
shares the same seed sequence. The role of miR-29 family
members in various fibrotic diseases such as renal and
liver fibrosis has been reported, and the results indicatethat they function through modulation of collagen related
gene expression and formation of extracellular matrix
[51,52]. The change in expression of miR-29b between
control and hypertonic dialysate groups was examined in
our microarray analysis. However, no significant difference
was observed. The inconsistency might result from the
variations in experimental systems, treatment duration,
time of assay, and sensitivity of detection methods.
Further investigation is required to evaluate the function
of miR-29b and other family members in pathogenesis of
peritoneal fibrosis.
Although an accumulating number of studies have
suggested the role of miRNAs in regulating EMT, only a
handful of them focus on peritoneal mesothelial cells
[23,53]. EMT involves trans-differentiation of mesothelial
cells into fibroblast-like cells and triggers the development
and progression of peritoneal fibrosis [25]. Cancer migra-
tion and metastasis share a similar mechanism: remodeling
of extracellular matrix and initiation of EMT. Several
studies have demonstrated that miR-100, miR-152 and
miR-497 are associated with the development of tumor and
tumor metastasis [54-56]. Thereby, we speculate that above
miRNAs may play similar roles in EMT of mesothelial cells
and the progression of peritoneal fibrosis. Although the
correlation between dysregulated miRNA expression and
EMT/peritoneal fibrosis was indicated by the present study,
the exact roles these miRNAs play are still unclear. In
addition, further studies should be conducted to determine
the targets of miRNAs involved in these processes and to
elucidate the underlying mechanism. Potential role of
the miRNA candidates in other cell types present in
the peritoneum, such as vascular endothelial cells and
infiltrating mononuclear cells, should also be investigated.
Conclusions
In the rat model of peritoneal fibrosis established by
intraperitoneal injection of 4.25% hypertonic dialysate,
a miRNA screen was performed and identified miRNA
candidates which might play roles in pathogenesis of
Lin et al. BMC Nephrology  (2015) 16:48 Page 8 of 9peritoneal fibrosis. Strong correlation between altered
expression of these miRNA candidates and epithelial-
to-mesenchymal transition was also indicated. We believe
that a better understanding of the roles these miRNAs
play in peritoneal fibrosis will lead to identification of
effective diagnostic markers and therapeutic targets in
patients with progressive peritoneal fibrosis and ultra-
filtration failure during long-term PD.
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